This Week in Psychedelics - 10.22.21

Cannabis

  • Luxembourg first in Europe to legalise growing and using cannabis (The Guardian)

  • Switzerland to legalise recreational and medical cannabis usage (The Local)

  • Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer (Marijuana Moment)

  • New York: Employers Are Prohibited from Testing Most Employees for Cannabis (NORML)

  • Top Mexican Senator Says Marijuana Legalization Bill May Be Taken Up Within Weeks (Marijuana Moment)

  • South Dakota Lawmakers Advance Marijuana Legalization Bill As Activists Pursue 2022 Ballot Initiative (Marijuana Moment)

  • Oregon illegal pot grows: More calls to send National Guard (AP News)

  • USPS Releases Final Rule Banning Mailing Of Hemp, CBD And Marijuana Vapes (Marijuana Moment)

  • Alabama Announces Medical Cannabis Licenses Won’t Be Available Until 2022 (High Times)

  • Impact Of Marijuana Legalization On Crime Reduction Is Being Underestimated, New Study Finds (Marijuana Moment)

  • Recreational Cannabis Law in Washington, D.C. May Soon Be Operational (High Times)

  • New York: Officials Advance Home Cultivation Regulations for Qualified Patients (NORML)

  • Minnesota Denies Coverage of Medical Marijuana for Injured Workers (High Times)

  • Brit jailed for 25 years in Dubai over CBD vape oil speaks of 'shocking' conditions in call to mum (ITV)

  • Indica and Sativa Labels Can’t Be Trusted, Study Indicates (High Times)

  • Americans Want To Live Where Marijuana Is Legal, Real Estate Survey Finds (Marijuana Moment)

  • Study: Cannabis Use Benefits ADHD Symptoms in Adults, According to Self-Reports (ADDitude)

LSD

  • LSD vs. Psilocybin Microdosing for Mental Health and Workplace productivity (The Third Wave)

  • Can You Overdose On LSD? This Is What To Know (Healing Maps)

Magic Mushrooms

  • Boris Johnson to consider calls to legalise magic mushroom drug psilocybin (BBC)

  • Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups (Psilocybin Alpha)

  • COMPASS Pathways is granted new US patent for crystalline psilocybin (Psilocybin Alpha)

  • Doing Shrooms Alone: The Art of Tripping Solo (DoubleBlind)

  • Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation (Psilocybin Alpha)

  • The “Unsung History” of Psilocybin Research: Gastón Guzmán and His Scientific Contribution (Chacruna)

  • Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product (Psilocybin Alpha)

  • Magic Mushrooms Could One Day Treat Depression. How Do They Work? (ScienceAlert)

MDMA

DMT

  • First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial (Psilocybin Alpha)

  • Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder (Psilocybin Alpha)

Novel Psychoactive Substances

  • Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies (Psilocybin Alpha)

  • Emyria passes MDMA analogue development milestone with Eurofins to lead extensive compound screening program (Proactive Investors)

Nitrous Oxide

  • Nang gang: Nitrous oxide helps alleviate depression, study finds (The Big Smoke)

Ketamine

  • Are Ketamine Clinics Paving the Way for Legal Psychedelic Therapy? (DoubleBlind)

  • Why Ketamine-Assisted Therapy Has Gone Mainstream (Forbes)

  • PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products (Psilocybin Alpha)

Miscellaneous

  • Easthampton, Mass. Decriminalizes Natural Psychedelics (DoubleBlind)

  • Oakland Psychedelics Activists Launch Initiative To Legalize Community-Based Sales With Support From City Council (Marijuana Moment)

  • DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone (Marijuana Moment)

  • Preventing Sexual Abuse in Psychedelic Therapy (Psychedelic Spotlight)

  • Bank Of America Cancels Account Of Marijuana And Psychedelics Research Institute Registered With DEA (Marijuana Moment)

  • Activist Apes Erect 2,001-Pound Monolith In Front Of DEA Headquarters, Demanding Feds ‘Evolve’ On Drug Policy (Marijuana Moment)

  • How Do I Talk To My Doctor About Psychedelics? (Truffle Report)

  • Addressing Abuse and Repair: An Open Letter to the Psychedelic Community (Chacruna)

  • This New Company Believes Psychedelics Can Treat Dementia (Psychedelic Spotlight)

  • Campaign Launches to Decriminalize Drugs in Washington, DC (Filter)

  • Can microdosing psychedelics impact an insurance application? (News24)

  • Even in a Year of Massive Reforms, Racist Myths Pervade the Drug Policy Debate (TalkingDrugs)

  • Countdown to ecstasy: how music is being used in healing psychedelic trips (The Guardian)

  • Homecoming: The Psychedelic Digital Companion Therapists Are Already Using (Forbes)

  • The Whitewashing of Psychedelic Medicine (Reality Sandwich)

  • Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton (Psilocybin Alpha)

  • Baltimore Study Boosts Movements to Decriminalize Drugs and Sex Work (Filter)

  • Carlos Santana still takes hallucinogens (MSN)

  • ‘Shrooms! Shamans! Kosher LSD! Why Los Angeles Is Suddenly Tripping Out (Los Angeles Magazine)

  • How Nutrition Can Improve the Psychedelic Experience (Psychedelic Spotlight)

  • Why creatives should microdose LSD and cannabis before big pitches (AdAge)

  • Psychedelics and Sports: Can They Propel Athletes to Unprecedented Pinnacles of Ability? (Psychedelic Spotlight)

  • Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders (Psilocybin Alpha)

  • The Neuroanatomy of a Psychedelic Trip: The Basics (Healing Maps)

  • atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.